Oct. 21 at 3:46 PM
$NAGE NAD-RBD, a Phase III multi-centre, randomised, double-blind, placebo-controlled study, will evaluate the efficacy of NAD-replenishment therapy in halting the progression of motor and cognitive dysfunction in individuals with iRBD. We plan to enrol 400 participants across 11 centres in Norway and treat them for 24–58 months
The primary objective of the project is to assess the clinical efficacy of NR in delaying the progression of motor dysfunction, cognitive dysfunction, or phenoconversion in individuals with iRBD.
Status: The protocol has been established. Recruitment is planned for Q4 2025.
Post NoPark startup Trials, (completion Q2 2025) where the results are known to the research team at this point, may suggest that NR showed a meaningful benefit in NoPark or why continue with NR in a new Phase III if NoPark was a fail? TBD of course.
https://www.helse-bergen.no/en/neuro-sysmed-english/clinical-studies-at-neuro-sysmed/parkinsons--clinical-studies/nad-rbd/
